Charles River Laboratories International, Inc. (CRL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRL SEC filings page.
Charles River Laboratories International, Inc. (CRL) reported $4.0B in revenue over the twelve months to Jun 27, 2026, down 0.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Stable revenue now supports far less reported profit, while cash generation remains buffered by noncash expense and restrained reinvestment.
From FY2023 to FY2025, revenue slipped from$4.1B to$4.0B while operating margin fell from15.0% to0.6% , indicating a sharp deterioration in operating economics without a comparable volume collapse. The simultaneous move from a11.5% net margin to-3.6% and a12.9% free-cash-flow margin shows that accounting earnings and cash production have temporarily become very different measures of performance.
FY2025 operating cash flow was
The financing structure became less debt-heavy as long-term debt declined from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Charles River Laboratories International, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Charles River Laboratories International, Inc. has an operating margin of 0.6%, meaning the company retains $1 of operating profit per $100 of revenue. This results in a moderate score of 50/100, indicating healthy but not exceptional operating efficiency. This is down from 5.6% the prior year.
Charles River Laboratories International, Inc.'s revenue declined 0.9% year-over-year, from $4.0B to $4.0B. This contraction results in a growth score of 26/100.
Charles River Laboratories International, Inc. has elevated debt relative to equity (D/E of 0.68), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 13/100, reflecting increased financial risk.
Charles River Laboratories International, Inc.'s current ratio of 1.29 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.
Charles River Laboratories International, Inc. converts 12.9% of revenue into free cash flow ($518.5M). This strong cash generation earns a score of 71/100.
Charles River Laboratories International, Inc. posts a -4.6% return on equity (ROE), meaning it loses $5 for every $100 of shareholders' equity. This results in a returns score of 44/100. This is down from 0.6% the prior year.
Charles River Laboratories International, Inc. scores 3.04, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($14.0B) relative to total liabilities ($3.9B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Charles River Laboratories International, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Charles River Laboratories International, Inc. reported a net loss of $144.3M while generating $737.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Charles River Laboratories International, Inc. earns $0.24 in operating income for every $1 of interest expense ($25.2M vs $107.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Charles River Laboratories International, Inc. generated $1.0B in revenue in Q2 2026. This represents a decrease of 2.7% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.
Charles River Laboratories International, Inc.'s EBITDA was $187.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.8% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.
Charles River Laboratories International, Inc. reported -$1.5M in net income in Q2 2026. This represents a decrease of 102.8% from the same quarter a year earlier. Against the prior quarter it is up 90.0%.
Charles River Laboratories International, Inc. earned -$0.03 per diluted share (EPS) in Q2 2026. This represents a decrease of 102.8% from the same quarter a year earlier. Against the prior quarter it is up 90.0%.
Cash & Balance Sheet
Charles River Laboratories International, Inc. generated $148.6M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 12.2% from the same quarter a year earlier. Against the prior quarter it is up 1102.1%.
Charles River Laboratories International, Inc. held $192.0M in cash against $2.6B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Charles River Laboratories International, Inc.'s operating margin was 11.9% in Q2 2026, reflecting core business profitability. This is up 2.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.
Charles River Laboratories International, Inc.'s net profit margin was -0.1% in Q2 2026, showing the share of revenue converted to profit. This is down 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.3 percentage points.
Charles River Laboratories International, Inc.'s ROE was -0.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Not reported for Q2 2026.
Capital Allocation
Charles River Laboratories International, Inc. spent $115.6M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 1472.3% from the same quarter a year earlier. Against the prior quarter it is down 44.5%.
Charles River Laboratories International, Inc. invested $31.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 11.9% from the same quarter a year earlier. Against the prior quarter it is down 44.4%.
Not reported for Q2 2026.
CRL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B-2.7% | $995.8M+1.2% | $994.2M-0.8% | $1.0B-0.5% | $1.0B+0.6% | $984.2M-2.7% | $1.0B-1.1% | $1.0B-1.6% |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $660.7M-0.6% |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $349.0M-3.5% |
| SG&A Expenses | $228.9M+19.5% | $159.4M-10.3% | $196.1M+0.2% | $177.6M-10.9% | $191.5M+12.8% | $177.8M-4.6% | $195.7M-0.7% | $199.2M+13.1% |
| Operating Income | $119.9M+19.7% | $119.9M+60.6% | -$283.4M-69.0% | $133.8M+14.0% | $100.1M-34.0% | $74.7M-40.7% | -$167.7M-226.2% | $117.4M-22.5% |
| EBITDA | $187.2M-14.8% | $187.0M-4.1% | -$205.2M-212.8% | $219.0M+6.5% | $219.6M-7.6% | $195.0M-7.7% | -$65.6M-130.7% | $205.6M-10.8% |
| Interest Expense | $30.3M+1.2% | $26.7M-4.1% | $23.8M-15.8% | $25.4M-16.1% | $30.0M-8.6% | $27.9M-20.3% | $28.2M-15.8% | $30.3M-10.2% |
| Income Tax | $53.9M+188.0% | -$15.1M-249.9% | -$17.8M-485.1% | $31.6M+51.1% | $18.7M-26.3% | $10.1M-58.8% | -$3.0M-115.4% | $20.9M-15.7% |
| Net Income | -$1.5M-102.8% | -$14.8M-158.3% | -$276.6M-28.9% | $54.4M-21.9% | $52.3M-44.4% | $25.5M-65.1% | -$214.5M-214.7% | $69.7M-20.3% |
| EPS (Basic) | -$0.03-102.8% | -$0.30-160.0% | -$5.57-32.9% | $1.11-17.2% | $1.06-39.4% | $0.50-61.8% | -$4.19-214.8% | $1.34-21.2% |
| EPS (Diluted) | -$0.03-102.8% | -$0.30-160.0% | -$5.56-33.3% | $1.10-17.3% | $1.06-39.1% | $0.50-61.5% | -$4.17-214.6% | $1.33-21.3% |
| Diluted Shares (Avg) | 48M-2.6% | 49M-3.7% | N/A | 49M-4.2% | 49M-4.9% | 51M-1.9% | N/A | 52M0.0% |
Not reported in any period shown, so not listed: R&D Expenses.
CRL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.5B-0.4% | $7.7B+2.0% | $7.1B-5.2% | $7.5B-6.1% | $7.6B-4.9% | $7.6B-7.0% | $7.5B-8.1% | $8.0B+5.2% |
| Current Assets | $1.5B+4.0% | $1.5B-1.2% | $1.4B+3.1% | $1.5B+2.5% | $1.5B-2.0% | $1.5B-9.7% | $1.4B-12.8% | $1.5B+3.5% |
| Cash & Equivalents | $192.0M+5.0% | $191.8M-16.4% | $213.8M+9.8% | $207.1M-1.5% | $182.8M+2.0% | $229.4M-29.9% | $194.6M-29.7% | $210.2M+33.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $346.3M+23.9% | $359.7M+24.0% | $299.1M+7.4% | $302.6M-10.0% | $279.6M-19.9% | $290.2M-19.7% | $278.5M-26.7% | $336.2M+14.8% |
| Accounts Receivable | $711.8M-7.3% | $700.3M-7.5% | $708.9M-1.7% | $734.5M-2.6% | $767.6M+0.7% | $756.6M-3.9% | $720.9M-7.6% | $754.2M-5.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $3.1B+4.8% | $3.0B+5.8% | $2.8B-2.9% | $2.9B-6.5% | $2.9B-4.7% | $2.9B-6.4% | $2.8B-8.0% | $3.1B+8.3% |
| Total Liabilities | $4.6B+11.6% | $4.7B+9.2% | $3.9B-2.4% | $4.1B-2.7% | $4.2B-0.3% | $4.3B-2.4% | $4.0B-11.4% | $4.2B-1.9% |
| Current Liabilities | $1.1B+5.0% | $1.1B+4.1% | $1.1B+12.7% | $1.1B+10.8% | $1.1B+14.0% | $1.1B+10.1% | $994.1M-5.8% | $1.0B+1.9% |
| Non-Current Liabilities | $3.5B+13.9% | $3.6B+10.9% | $2.8B-7.3% | $2.9B-7.0% | $3.1B-4.6% | $3.3B-5.9% | $3.0B-13.1% | $3.2B-3.0% |
| Long-Term Debt | $2.6B+12.3% | $2.7B+6.1% | $2.1B-4.6% | $2.2B-6.1% | $2.3B-3.2% | $2.5B-5.6% | $2.2B-15.4% | $2.3B-7.5% |
| Total Equity | $2.8B-15.3% | $2.9B-7.9% | $3.2B-8.6% | $3.4B-10.0% | $3.4B-9.9% | $3.2B-12.3% | $3.5B-3.8% | $3.8B+14.4% |
| Retained Earnings | $1.4B-27.4% | $1.4B-25.2% | $1.4B-23.4% | $1.9B-8.4% | $1.9B-8.0% | $1.8B-6.2% | $1.8B-4.0% | $2.1B+23.4% |
CRL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $179.7M-12.2% | $41.1M-76.1% | $147.5M-7.4% | $213.8M-15.1% | $204.6M+5.7% | $171.7M+32.2% | $159.4M-27.9% | $251.8M+22.6% |
| Depreciation & Amortization | $67.3M-43.7% | $67.2M-44.2% | $78.3M-23.3% | $85.2M-3.4% | $119.5M+38.8% | $120.4M+41.0% | $102.1M+26.8% | $88.2M+11.8% |
| Stock-Based Compensation | N/A | $22.4M+70.4% | N/A | N/A | N/A | $13.1M-21.5% | N/A | N/A |
| Capital Expenditures | $31.1M-11.9% | $55.9M-5.8% | $89.0M+17.6% | $35.6M-8.1% | $35.3M-10.6% | $59.3M-25.0% | $75.6M-3.5% | $38.7M-41.3% |
| Free Cash Flow | $148.6M-12.2% | -$14.8M-113.2% | $58.6M-30.1% | $178.2M-16.3% | $169.3M+9.9% | $112.4M+121.5% | $83.7M-41.3% | $213.1M+52.7% |
| Investing Cash Flow | $28.1M+175.2% | -$407.8M-796.8% | -$92.8M-21.9% | -$33.7M-58.0% | -$37.3M+39.6% | -$45.5M+47.0% | -$76.1M+68.1% | -$21.3M+73.2% |
| Financing Cash Flow | -$164.7M+27.4% | $347.7M+430.1% | -$51.9M+31.6% | -$152.6M+26.5% | -$226.9M+20.6% | -$105.3M-674.1% | -$75.9M-161.4% | -$207.5M-27.4% |
| Share Buybacks | $115.6M+1472.3% | $208.3M-41.0% | $96K-22.6% | $93K-99.9% | $7.4M-17.5% | $353.1M+3676.4% | $124K-10.8% | $100.8M+265126.3% |
Not reported in any period shown, so not listed: Dividends Paid.
CRL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 34.6%-0.7pp |
| Operating Margin | 11.9%+2.2pp | 12.0%+4.5pp | -28.5%-11.8pp | 13.3%+1.7pp | 9.7%-5.1pp | 7.6%-4.9pp | -16.7%-29.8pp | 11.6%-3.1pp |
| Net Margin | -0.1%-5.2pp | -1.5%-4.1pp | -27.8%-6.4pp | 5.4%-1.5pp | 5.1%-4.1pp | 2.6%-4.6pp | -21.4%-39.8pp | 6.9%-1.6pp |
| Return on Equity | -0.1%-1.6pp | -0.5%-1.3pp | -8.7%-2.5pp | 1.6%-0.2pp | 1.6%-1.0pp | 0.8%-1.2pp | -6.2%-11.4pp | 1.8%-0.8pp |
| Return on Assets | 0.0%-0.7pp | -0.2%-0.5pp | -3.9%-1.0pp | 0.7%-0.1pp | 0.7%-0.5pp | 0.3%-0.5pp | -2.9%-5.1pp | 0.9%-0.3pp |
| Current Ratio | 1.350.0x | 1.36-0.1x | 1.29-0.1x | 1.37-0.1x | 1.36-0.2x | 1.43-0.3x | 1.41-0.1x | 1.480.0x |
| Debt-to-Equity | 0.92+0.2x | 0.91+0.1x | 0.680.0x | 0.640.0x | 0.700.0x | 0.79+0.1x | 0.65-0.1x | 0.62-0.1x |
| Asset Turnover | 0.130.0x | 0.130.0x | 0.140.0x | 0.130.0x | 0.140.0x | 0.130.0x | 0.130.0x | 0.130.0x |
| FCF Margin | 14.8%-1.6pp | -1.5%-12.9pp | 5.9%-2.5pp | 17.7%-3.4pp | 16.4%+1.4pp | 11.4%+6.4pp | 8.3%-5.7pp | 21.1%+7.5pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. CRL | FY2025 | $4.0B | -$144.3M | -3.6% | $14.0B | 40/100 |
| Guardant Health, Inc. GH | FY2025 | $982.0M | -$416.3M | -42.4% | $23.9B | 63/100 |
| QIAGEN N.V. QGEN | FY2025 | $2.1B | $424.9M | 20.3% | $9.0B | 65/100 |
| Revvity, Inc. RVTY | FY2025 | $2.9B | $241.2M | 8.5% | $17.1B | 51/100 |
| RadNet, Inc. RDNT | FY2025 | $2.0B | -$18.6M | -0.9% | $5.4B | 44/100 |
| Sotera Health Company SHC | FY2025 | $1.2B | $77.9M | 6.7% | $5.3B | 57/100 |
Where Charles River Laboratories International, Inc. Ranks
Frequently Asked Questions
What is Charles River Laboratories International, Inc.'s annual revenue?
Charles River Laboratories International, Inc. (CRL) reported $4.0B in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Charles River Laboratories International, Inc.'s revenue growing?
Charles River Laboratories International, Inc. (CRL) revenue declined by 0.9% year-over-year, from $4.0B to $4.0B in fiscal year 2025.
Is Charles River Laboratories International, Inc. profitable?
No, Charles River Laboratories International, Inc. (CRL) reported a net income of -$144.3M in fiscal year 2025, with a net profit margin of -3.6%.
What is Charles River Laboratories International, Inc.'s EBITDA?
Charles River Laboratories International, Inc. (CRL) had EBITDA of $428.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Charles River Laboratories International, Inc. have?
As of fiscal year 2025, Charles River Laboratories International, Inc. (CRL) had $213.8M in cash and equivalents against $2.1B in long-term debt.
What is Charles River Laboratories International, Inc.'s operating margin?
Charles River Laboratories International, Inc. (CRL) had an operating margin of 0.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Charles River Laboratories International, Inc.'s net profit margin?
Charles River Laboratories International, Inc. (CRL) had a net profit margin of -3.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Charles River Laboratories International, Inc.'s return on equity (ROE)?
Charles River Laboratories International, Inc. (CRL) has a return on equity of -4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Charles River Laboratories International, Inc.'s free cash flow?
Charles River Laboratories International, Inc. (CRL) generated $518.5M in free cash flow during fiscal year 2025. This represents a 3.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Charles River Laboratories International, Inc.'s operating cash flow?
Charles River Laboratories International, Inc. (CRL) generated $737.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Charles River Laboratories International, Inc.'s total assets?
Charles River Laboratories International, Inc. (CRL) had $7.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Charles River Laboratories International, Inc.'s capital expenditures?
Charles River Laboratories International, Inc. (CRL) invested $219.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Charles River Laboratories International, Inc.'s current ratio?
Charles River Laboratories International, Inc. (CRL) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.
What is Charles River Laboratories International, Inc.'s debt-to-equity ratio?
Charles River Laboratories International, Inc. (CRL) had a debt-to-equity ratio of 0.68 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Charles River Laboratories International, Inc.'s return on assets (ROA)?
Charles River Laboratories International, Inc. (CRL) had a return on assets of -2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Charles River Laboratories International, Inc.'s P/E ratio?
Charles River Laboratories International, Inc. (CRL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 27, 2026). The market capitalization is $14.0B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Charles River Laboratories International, Inc.'s price-to-sales ratio?
Charles River Laboratories International, Inc. (CRL) trades at 3.5x sales, its market capitalization divided by revenue of $4.0B revenue, trailing 12 months to June 27, 2026. The market capitalization is $14.0B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Charles River Laboratories International, Inc.'s Altman Z-Score?
Charles River Laboratories International, Inc. (CRL) has an Altman Z-Score of 3.04, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Charles River Laboratories International, Inc.'s Piotroski F-Score?
Charles River Laboratories International, Inc. (CRL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Charles River Laboratories International, Inc.'s earnings high quality?
Charles River Laboratories International, Inc. (CRL) reported a net loss of $144.3M while generating $737.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Charles River Laboratories International, Inc. cover its interest payments?
Charles River Laboratories International, Inc. (CRL) has an interest coverage ratio of 0.24x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Charles River Laboratories International, Inc.?
Charles River Laboratories International, Inc. (CRL) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.